We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+12.88%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$3.32B
AUM Growth
+$622M
Cap. Flow
+$387M
Cap. Flow %
11.66%
Top 10 Hldgs %
45.52%
Holding
112
New
12
Increased
30
Reduced
18
Closed
14

Top Buys

Rank Stock Value
1
KO icon
Coca-Cola
KO
+$58.2M
2
DKS icon
Dick's Sporting Goods
DKS
+$48.3M
3
GEHC icon
GE HealthCare
GEHC
+$37.1M
4
DHR icon
Danaher
DHR
+$31.2M
5
GE icon
GE Aerospace
GE
+$24M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$95.9M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$92.5M
3
MSFT icon
Microsoft
MSFT
+$35.3M
4
CMG icon
Chipotle Mexican Grill
CMG
+$27.1M
5
UAL icon
United Airlines
UAL
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 48.97%
2 Technology 9.89%
3 Consumer Discretionary 5.64%
4 Financials 4.91%
5 Communication Services 4.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
51
Monte Rosa Therapeutics
GLUE
$1.35B
$15.2M 0.46%
3,360,000
+1,796,202
+115% +$8.01M
MRNA icon
52
Moderna
MRNA
$23.1B
$14.3M 0.43%
517,163
– –
KYMR icon
53
Kymera Therapeutics
KYMR
$8.89B
$12M 0.36%
+275,000
New +$9.47M
RCKT icon
54
Rocket Pharmaceuticals
RCKT
$382M
$10.2M 0.31%
4,143,333
+641,333
+18% +$3.25M
MOLN
55
Molecular Partners
MOLN
$152M
$8.49M 0.26%
2,221,494
– –
TSHA icon
56
Taysha Gene Therapies
TSHA
$1.85B
$7.43M 0.22%
+3,217,449
New +$6.99M
PROK icon
57
ProKidney
PROK
$337M
$7.31M 0.22%
12,341,266
– –
WHWK
58
Whitehawk Therapeutics
WHWK
$236M
$6.92M 0.21%
3,700,000
– –
CTNM
59
Contineum Therapeutics
CTNM
$571M
$6.83M 0.21%
1,720,000
– –
ABT icon
60
Abbott
ABT
$186B
$5.51M 0.17%
40,520
-18,300
-31% -$2.41M
IFRX icon
61
InflaRx
IFRX
$271M
$5.12M 0.15%
6,483,910
– –
ZURA icon
62
Zura Bio
ZURA
$562M
$5.1M 0.15%
4,860,939
– –
EXAS
63
DELISTED
Exact Sciences
EXAS
$5M 0.15%
94,100
– –
STRO icon
64
Sutro Biopharma
STRO
$416M
$4.63M 0.14%
648,832
-97,418
-13% -$797K
REGN icon
65
Regeneron Pharmaceuticals
REGN
$80.5B
$4.53M 0.14%
+8,630
New +$4.82M
COR icon
66
Cencora
COR
$61.4B
$3.74M 0.11%
12,488
– –
ELAN icon
67
Elanco Animal Health
ELAN
$11.4B
$3.62M 0.11%
253,600
– –
KZR
68
DELISTED
Kezar Life Sciences
KZR
$3.28M 0.1%
716,759
– –
TMO icon
69
Thermo Fisher Scientific
TMO
$217B
$3.2M 0.1%
7,900
– –
ISRG icon
70
Intuitive Surgical
ISRG
$133B
$2.83M 0.09%
5,200
– –
DXCM icon
71
DexCom
DXCM
$31.8B
$2.77M 0.08%
31,680
– –
SYK icon
72
Stryker
SYK
$130B
$2.32M 0.07%
5,860
– –
MTD icon
73
Mettler-Toledo International
MTD
$28.5B
$2.31M 0.07%
1,964
– –
MDT icon
74
Medtronic
MDT
$110B
$2.18M 0.07%
25,060
– –
NTRA icon
75
Natera
NTRA
$45.4B
$1.71M 0.05%
10,100
– –
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return

Suvretta Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Suvretta Capital Management held 112 positions worth $3.32B, up 23% from $2.69B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Suvretta Capital Management deployed $387M of net new capital in Q2 2025, opening 12 new positions and adding to 30 existing holdings. Its largest new stake was Dick's Sporting Goods: 260,465 shares worth $51.5M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Insmed, an estimated $95.9M trimmed.

  • Suvretta Capital Management's largest Q2 2025 buy was Dick's Sporting Goods: 260,465 shares worth $51.5M.
  • Suvretta Capital Management added most to Coca-Cola in Q2 2025, an estimated $58.2M increase.
  • Suvretta Capital Management's biggest Q2 2025 reduction was Insmed, cutting an estimated $95.9M.
  • Suvretta Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $92.5M.
  • Suvretta Capital Management's ten largest holdings make up 46% of its $3.32B portfolio in Q2 2025.
  • Suvretta Capital Management opened 12 new positions and closed 14 in Q2 2025.
  • Suvretta Capital Management's portfolio value rose 23% quarter-over-quarter to $3.32B.

Based on Suvretta Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.